Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNOs-SBRT: Atezolizumab, Tiragolumab, and SBRT in Oligometastatic Cancers
NCT05259319Phase 1Unknown
- Sponsor
- Centre Georges-François Leclerc
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tiragolumab in non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma (RCC) and 1 more, sponsored by Centre Georges-François Leclerc. Primary endpoints: Safety of SBRT with sequential administration of immunotherapy at 5 weeks and Safety of SBRT with concomitant administration of immunotherapy at 4 weeks. Status: unknown.
02
Drugs
tiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)bladder cancerrenal cell carcinoma (RCC)head and neck carcinoma (HNC)
Beyond the preview
Go deeper on NCT05259319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05259319.